Market Insights report
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.
What's included?
Anti-Diabetes Drugs are one of the largest markets of the Pharmaceuticals market. The Anti-Diabetes Drugs market is experiencing steady growth. This development is driven by the number of patients, which is projected to increase continuously over the next years. The majority of cases are type 2 diabetes, which is associated with obesity, and the number of obese people worldwide is projected to increase by a few percent every year. Additionally, the market is driven by an increasing awareness of health issues and by improving access to healthcare in emerging countries.
Overview
Market numbers
We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)